What is adipotide (FTPP), and is the fat-loss peptide safe?

The short answer

Adipotide (FTPP) is a pro-apoptotic peptide that kills the blood vessels feeding white fat, causing fat cells to die. In obese monkeys it cut body weight ~11% in 28 days — but with dose-limiting kidney toxicity. There are no human trials, it is not approved, and self-use is genuinely dangerous.

Evidence tier: Tier 3 — preclinical only (mouse and monkey). No human clinical trials. Educational content, not medical advice.

The key points:

• A pro-apoptotic peptide that destroys fat-tissue blood vessels, not appetite
• ~11% weight loss in monkeys in 28 days — but that's the whole human-relevance ceiling
• Dose-limiting kidney toxicity — the reason it never advanced
• No human trials, not approved — self-use is high-risk and unwise

For evidence-based fat loss instead, see the GLP-1 complete guide.

What is adipotide (FTPP)?

Evidence tier: 2 — established mechanism from preclinical work.

Adipotide — also called FTPP (fat-targeting pro-apoptotic peptide) or prohibitin-targeting peptide 1 — is an experimental peptidomimetic with a genuinely unusual mechanism. It's a two-part molecule: a homing domain that binds prohibitin, a protein marker on the blood-vessel lining that feeds white adipose (fat) tissue, fused to a pro-apoptotic domain that triggers programmed cell death once it's delivered there. In plain terms, adipotide finds the vasculature supplying fat, kills those endothelial cells, and the fat cells — starved of their blood supply — die off (Kolonin et al. 2004, Nature Medicine, PMID 15133506).

This is a completely different strategy from every mainstream weight-loss drug. GLP-1 and amylin peptides work on appetite and satiety signaling; adipotide ignores appetite and attacks the tissue directly, essentially trying to ablate fat by cutting off its circulation. The concept traces back to phage-display work that identified the CKGGRAKDC peptide sequence homing to fat vasculature and established prohibitin as a vascular address for adipose tissue (related mechanism paper, PMC2844838). The elegance of the targeting is real. But "kill the blood supply to a tissue" is an inherently aggressive approach, and — as the animal data show — it doesn't stay perfectly confined to fat.

How much fat did adipotide cause monkeys to lose?

Evidence tier: 3 — non-human primate study.

The pivotal evidence is a 2011 study in spontaneously obese rhesus monkeys, published in Science Translational Medicine (Barnhart et al. 2011, PMID 22072637). Monkeys given daily subcutaneous adipotide for 28 days lost about 11% of body weight, with roughly a 39% reduction in total body fat on imaging, plus meaningful improvements in insulin sensitivity. Earlier work in obese mice had shown even larger relative weight reductions over a similar timeframe (Kolonin et al. 2004, PMID 15133506).

On the surface those are striking numbers — targeted fat ablation that also improves metabolic markers. But two honest qualifications dominate. First, this is non-human primate and rodent data only; impressive animal fat loss has a long history of failing to translate to safe human therapy. Second, and more importantly, the same study that reported the weight loss also reported the toxicity that ended adipotide's momentum. The efficacy and the danger came from the same experiment — you cannot cite the 11% figure honestly without the kidney finding attached to it. That's the crux of the entire adipotide story, and it's covered next.

What is the dose-limiting kidney toxicity?

Evidence tier: 3 — non-human primate safety data.

This is the decisive, non-negotiable part. In the same 2011 primate study, adipotide caused dose-dependent kidney toxicity — specifically injury to the renal proximal tubules, seen as degenerative and necrotic changes in kidney tubular cells and reflected in altered renal markers (Barnhart et al. 2011, PMID 22072637). It was described as reversible in that study at the doses tested, but it was dose-limiting: the kidney damage set the ceiling on how much drug could be given, which is exactly the kind of finding that stops a compound from progressing.

Why the kidney? The likely explanation is that prohibitin — the "address" adipotide homes to — isn't exclusively on fat vasculature. The kidney's high blood flow and filtration role make it especially vulnerable to a circulating pro-apoptotic agent, so a drug designed to kill blood vessels in one tissue plausibly hits the renal vasculature too. This is the fundamental problem with a "destroy the tissue" approach: perfect targeting is extraordinarily hard, and the failure mode isn't a mild side effect — it's organ damage. A drug whose defining efficacy study also documents dose-limiting nephrotoxicity is not a candidate you experiment with on yourself, and this is the single most important fact to take away about adipotide.

Are there human trials of adipotide?

Evidence tier: 3 — regulatory/development status.

No — and this is essential to understand. Despite widespread online marketing of "adipotide" as a fat-loss peptide, there is no completed, credible human clinical trial demonstrating it is safe or effective in people, and it is not approved by the FDA, EMA, or any comparable regulator. An early-phase human study in cancer-associated obesity was discussed years ago, but adipotide never became an established clinical therapy, and its development effectively stalled — the dose-limiting kidney toxicity in primates being the obvious reason a pro-apoptotic, vasculature-destroying peptide is a hard sell for chronic use in otherwise healthy people.

So the entire human-relevant safety and efficacy picture rests on animal data plus mechanistic reasoning — the very definition of Tier 3, preclinical evidence. That means anyone considering adipotide would be, in effect, running an uncontrolled experiment on themselves with a compound whose best data come with a kidney-damage warning. Weigh that against the approved, monitored, human-trialed options that actually exist for weight loss. The gap between "worked in monkeys" and "safe for a person to inject at home" is enormous here, and adipotide sits about as far on the dangerous side of that gap as a weight-loss compound can.

Should you use adipotide?

Evidence tier: 2 — safety and sourcing judgment.

No. This is one of the clearest "do not self-administer" cases in the peptide space. Adipotide is not approved, has no supporting human trials, works by an inherently aggressive cell-killing mechanism, and its best animal study documents dose-limiting nephrotoxicity. Anything sold online as "adipotide" or "FTPP" is a gray-market research chemical with all the usual authenticity, purity, dosing, and sterility problems (spotting counterfeit and gray-market peptides) — except here the underlying compound is dangerous even if the vial is exactly what it claims to be. There is no "correct" home dose, because the safe human dose was never established.

If your goal is real, sustainable fat loss, the honest recommendation is to ignore adipotide entirely and look at interventions with actual human evidence and safety monitoring — the approved appetite-hormone therapies used under medical supervision, plus lifestyle fundamentals. Adipotide is a scientifically interesting proof-of-concept for targeted fat-tissue ablation, and it may inform future drug design, but as a thing to put in your own body in 2026 it is high-risk and abandoned for good reason. For a broader sense of how to grade preclinical "miracle in mice" compounds against reality, see our longevity peptide stacks evidence debunk.

Limitations

This is educational content, not medical advice.

• Preclinical only — evidence is mouse and monkey; no credible human efficacy or safety trials.
• Dose-limiting kidney toxicity — the defining primate study documented renal proximal-tubule damage.
• Not approved by the FDA, EMA, or any comparable regulator; development stalled.
• Aggressive mechanism — it kills fat-tissue blood vessels, an inherently high-risk approach.
• Gray-market "adipotide" is doubly risky — unverified product and a dangerous underlying compound.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Adipotide (FTPP) is a pro-apoptotic peptide that destroys the blood vessels feeding white fat, causing targeted fat-cell death — a genuinely novel mechanism. In obese monkeys it produced about 11% weight loss and a ~39% drop in body fat over 28 days, with improved insulin sensitivity. But the same pivotal study reported dose-limiting kidney toxicity, injury to the renal tubules that capped how much could be given and is the obvious reason the compound never became a real therapy. There are no credible human trials, it is not approved anywhere, and its "adipotide" gray-market versions are dangerous even when authentic, because the compound itself carries organ-toxicity risk and has no established safe human dose. Treat adipotide as an interesting but abandoned preclinical concept — not a fat-loss option for any human to self-administer.

Related on this site

• GLP-1 complete guide
• AOD-9604 fat-loss reality check
• Longevity peptide stacks — evidence debunk
• Spotting counterfeit peptides
• Our evidence-tier framework

References

• Kolonin MG, et al. 2004. Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine 10(6):625–632. PMID 15133506 — original prohibitin-targeting peptide (CKGGRAKDC) in obese mice.
• Barnhart KF, et al. 2011. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine 3(108):108ra112. PMID 22072637 — the pivotal primate efficacy AND dose-limiting renal toxicity study.
• Peptide designed to elicit apoptosis in adipose tissue endothelium reduces food intake and body weight. PMC. PMC2844838 — mechanism of adipose-vasculature-targeted apoptosis.